Reaching Precision in Cancer Therapy Through Patient-Derived MicroOrganoSpheres, Flow Cytometry Analysis, and Molecular Profiling

Sponsored by: Sony Biotechnology

3 +50pts

Speakers

David Hsu, PhD

Associate Professor of Medicine, Duke University School of Medicine, Duke Cancer Institute
BIOGRAPHY
Ryan Mote, PhD

Science and Technology Advisor
10x Genomics
BIOGRAPHY

Event Date & Time

Date: May 22, 2024

Time: 8:00 AM (PDT), 11:00 AM (EDT), 5:00 PM (CEST)

Abstract

Precision medicine aims to match the right therapy to the right patient at the right time, improving efficacy and reducing side effects. In this webinar, Dr. Hsu discusses his work to develop personalized treatments for gastrointestinal (GI) cancer patients by creating patient-derived tumor models of cancer (PDMC) that predict how well a patient will respond to therapy. The approach includes a new miniature MicroOrganoSphere™ (MOS™) 3-D tissue model. In his work, Dr. Hsu utilizes the SH800 Cell Sorter to analyze and validate MOS and 10x Genomics’ Single Cell 3′ chemistry to perform molecular profiling of these clinical samples. Dr. Hsu’s promising technology is currently undergoing a clinical trial for colorectal cancer at Duke University.

Learning Objectives:

Understand the innovative features of MOS and assess their ability to accurately represent a patient's unique tumor landscape, while contrasting them with traditional cancer treatments
Discover the contribution of 10x Genomics technology in supporting and enhancing the development of this precision oncology platform
Explore the capabilities of the SH800 Cell Sorter in the development of precision therapies utilizing PDMC

Who Should Attend?

Oncologists, researchers, pharmaceutical professionals, clinicians, regulatory experts, and patient advocates interested in precision medicine and cancer care.

Webinars will be available for unlimited on-demand viewing after live event.